Elios Therapeutics
"Elios Therapeutics is a biopharmaceutical company developing a portfolio of innovative personalized therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types."
"Elios' lead therapeutic candidate is the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, a personalized therapeutic cancer vaccine that uses a proprietary particle delivery system to stimulate the body's immune system to recognize cancer cells as foreign pathogens and fight a patient's specific cancer. For more information, please visit www.eliostherapeutics.com."
Latest Elios Therapeutics News & Features
10 February 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze